Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

This page features the latest news about the Eli Lilly DRC stock. Eli Lilly stock soars to ... said Tuesday its weight loss drug reduced the risk of developing type 2 diabetes by 94% in ...

ByReuters • Nov 22, 2024 China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug (Reuters) - Eli Lilly (NYSE:LLY) and Hong Kong-listed Laekna will collaborate to ...

Skyworks says its share of the business to supply Apple will fall and cut into revenue, Qualcomm tumbles after earnings, Eli Lilly stock rises on upbeat guidance ... for their role in illegal ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide. The US ...

Eli Lilly has been unable to secure ... and it remains to be seen if either drug will hit the mark in phase 3. Lilly's head of neuroscience R&D Anne White said the company is confident that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...